JP2019531274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531274A5 JP2019531274A5 JP2019511947A JP2019511947A JP2019531274A5 JP 2019531274 A5 JP2019531274 A5 JP 2019531274A5 JP 2019511947 A JP2019511947 A JP 2019511947A JP 2019511947 A JP2019511947 A JP 2019511947A JP 2019531274 A5 JP2019531274 A5 JP 2019531274A5
- Authority
- JP
- Japan
- Prior art keywords
- bis
- oxy
- biphenyl
- dimethyl
- diyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 amino, carboxy Chemical group 0.000 claims 187
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 83
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 64
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 52
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 claims 46
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 28
- 235000010290 biphenyl Nutrition 0.000 claims 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 22
- 125000004076 pyridyl group Chemical group 0.000 claims 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 20
- 125000005843 halogen group Chemical group 0.000 claims 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 14
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000003386 piperidinyl group Chemical group 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 239000004146 Propane-1,2-diol Substances 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims 10
- 229960004063 propylene glycol Drugs 0.000 claims 10
- 235000013772 propylene glycol Nutrition 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 9
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims 8
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 claims 8
- DBXBTMSZEOQQDU-UHFFFAOYSA-N 3-hydroxyisobutyric acid Chemical compound OCC(C)C(O)=O DBXBTMSZEOQQDU-UHFFFAOYSA-N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002883 imidazolyl group Chemical group 0.000 claims 5
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 5
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 4
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 claims 4
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 4
- 125000004450 alkenylene group Chemical group 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 3
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 235000019260 propionic acid Nutrition 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- UXOQCYFKGDPUDV-PLXFJCCSSA-N (2S,4R)-4-hydroxy-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidine-2-carboxylic acid Chemical compound O[C@@H]1C[C@H](N(C1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)C(=O)O UXOQCYFKGDPUDV-PLXFJCCSSA-N 0.000 claims 2
- PKCXYIGMQIXBHG-YOQGVNIDSA-N (3R)-1-[3-[3-[3-[2-[(3R)-3-hydroxypyrrolidin-1-yl]ethyl]-2,3-dihydro-1,4-benzodioxin-6-yl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCC1OC2=C(OC1)C=CC(=C2)C=1C(=C(OCCCN2C[C@@H](CC2)O)C=CC=1)C PKCXYIGMQIXBHG-YOQGVNIDSA-N 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 2
- SPJPZSUFBQISRE-UHFFFAOYSA-N 1-[3-[2-methyl-3-(2-methylphenyl)phenoxy]propyl]pyrrolidin-3-ol Chemical compound OC1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C=CC=C1)C)C SPJPZSUFBQISRE-UHFFFAOYSA-N 0.000 claims 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N 4-hydroxyproline Chemical compound OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 2
- FGKJLKRYENPLQH-UHFFFAOYSA-N isocaproic acid Chemical compound CC(C)CCC(O)=O FGKJLKRYENPLQH-UHFFFAOYSA-N 0.000 claims 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 2
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims 2
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- ZAMUNOUDPJRWIJ-QPPBQGQZSA-N (2S)-2-hydroxy-3-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]propanoic acid Chemical compound O[C@H](C(=O)O)CNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C ZAMUNOUDPJRWIJ-QPPBQGQZSA-N 0.000 claims 1
- SHMLWSKIQITORU-VMPREFPWSA-N (2S)-3-[3-[3-[3-[3-[[(2S)-2,3-dihydroxypropyl]-(2-pyridin-3-ylethyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]propane-1,2-diol Chemical compound O[C@@H](CN(CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCNC[C@@H](CO)O)C)C)CCC=1C=NC=CC=1)CO SHMLWSKIQITORU-VMPREFPWSA-N 0.000 claims 1
- XUVCRLNALYWPFO-DFHRPNOPSA-N (2S)-3-hydroxy-2-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]-2-methylpropanoic acid Chemical compound OC[C@](C(=O)O)(C)NCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C XUVCRLNALYWPFO-DFHRPNOPSA-N 0.000 claims 1
- IQYCVHPCIZMJIG-JUQKIHQQSA-N (2S,3S)-3-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]-3-phenylpropane-1,2-diol Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN[C@H]([C@@H](CO)O)C1=CC=CC=C1)C)C IQYCVHPCIZMJIG-JUQKIHQQSA-N 0.000 claims 1
- SPJPZSUFBQISRE-GOSISDBHSA-N (3R)-1-[3-[2-methyl-3-(2-methylphenyl)phenoxy]propyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C=CC=C1)C)C SPJPZSUFBQISRE-GOSISDBHSA-N 0.000 claims 1
- PJFDIUZZYNDMBT-RUZDIDTESA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-(3-piperidin-1-ylpropoxy)phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN1CCCCC1)C PJFDIUZZYNDMBT-RUZDIDTESA-N 0.000 claims 1
- UTWZLLUIGZQEHS-XMMISQBUSA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[(1-methylpiperidin-3-yl)methoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCC1CN(CCC1)C)C UTWZLLUIGZQEHS-XMMISQBUSA-N 0.000 claims 1
- AOTXMUNSPVUYKX-RUZDIDTESA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[3-(2-pyrazol-1-ylethylamino)propoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound N1(N=CC=C1)CCNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C AOTXMUNSPVUYKX-RUZDIDTESA-N 0.000 claims 1
- YFWBKLCOKIURAV-GDLZYMKVSA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[3-[methyl(2-phenylethyl)amino]propoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN(CCC1=CC=CC=C1)C)C YFWBKLCOKIURAV-GDLZYMKVSA-N 0.000 claims 1
- IUYQJMVGGQCYAW-HHHXNRCGSA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[3-[methyl(pyridin-2-ylmethyl)amino]propoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN(CC1=NC=CC=C1)C)C IUYQJMVGGQCYAW-HHHXNRCGSA-N 0.000 claims 1
- ZMDHASBCNOHLFM-HHHXNRCGSA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[3-[methyl(pyridin-4-ylmethyl)amino]propoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN(CC1=CC=NC=C1)C)C ZMDHASBCNOHLFM-HHHXNRCGSA-N 0.000 claims 1
- JCMVCJJPQVNXSQ-AREMUKBSSA-N (3R)-1-[3-[2-methyl-3-[2-methyl-3-[3-[methyl-[2-[2-(methylamino)ethoxy]ethyl]amino]propoxy]phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN(CCOCCNC)C)C JCMVCJJPQVNXSQ-AREMUKBSSA-N 0.000 claims 1
- UDCOHOFRJVUEGM-AREMUKBSSA-N (3R)-1-[3-[2-methyl-3-[3-(3-phenylpropoxy)phenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=CC(=CC=C1)OCCCC1=CC=CC=C1 UDCOHOFRJVUEGM-AREMUKBSSA-N 0.000 claims 1
- YHEYJBXAADEELQ-FGZHOGPDSA-N (3R)-1-[3-[3-[2-chloro-3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]phenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound ClC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C YHEYJBXAADEELQ-FGZHOGPDSA-N 0.000 claims 1
- VSJTZCLPKHRPRH-AREMUKBSSA-N (3R)-1-[3-[3-[3-[3-(3-imidazol-1-ylpropylamino)propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound N1(C=NC=C1)CCCNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C VSJTZCLPKHRPRH-AREMUKBSSA-N 0.000 claims 1
- ZVPPJPUZOIVUTB-GDLZYMKVSA-N (3R)-1-[3-[3-[3-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound COC=1C=C2CCN(CC2=CC=1OC)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C ZVPPJPUZOIVUTB-GDLZYMKVSA-N 0.000 claims 1
- XNPYNCNECHZDJZ-QZWVJJBASA-N (3R)-1-[3-[3-[3-[3-[(2-hydroxy-1-pyridin-4-ylethyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound OCC(C1=CC=NC=C1)NCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C XNPYNCNECHZDJZ-QZWVJJBASA-N 0.000 claims 1
- BNNLKLMGJWJKAC-QZWVJJBASA-N (3R)-1-[3-[3-[3-[3-[(2-hydroxy-2-pyridin-3-ylethyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound OC(CNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)C=1C=NC=CC=1 BNNLKLMGJWJKAC-QZWVJJBASA-N 0.000 claims 1
- FNOQQPWACKVFEW-DNQXCXABSA-N (3R)-1-[3-[3-[3-[3-[(3R)-3-fluoropyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound F[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C FNOQQPWACKVFEW-DNQXCXABSA-N 0.000 claims 1
- IYMILTTVAXIHRW-JWQCQUIFSA-N (3R)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]piperidine-3-carboxylic acid Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CCC1)C(=O)O)C)C IYMILTTVAXIHRW-JWQCQUIFSA-N 0.000 claims 1
- HPXNLRDTKCJCDZ-DNQXCXABSA-N (3R)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C HPXNLRDTKCJCDZ-DNQXCXABSA-N 0.000 claims 1
- IXHPUSSTLKYZHV-DNQXCXABSA-N (3R)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-4-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=CC(=CC=C1C)OCCCN1C[C@@H](CC1)O IXHPUSSTLKYZHV-DNQXCXABSA-N 0.000 claims 1
- VTJJWWVIJXQBIQ-DNQXCXABSA-N (3R)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=CC(=CC=C1)OCCCN1C[C@@H](CC1)O VTJJWWVIJXQBIQ-DNQXCXABSA-N 0.000 claims 1
- IEZQRFAPDCUVGU-RUZDIDTESA-N (3R)-1-[3-[3-[3-[3-[2-(4-chloropyrazol-1-yl)ethylamino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound ClC=1C=NN(C=1)CCNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C IEZQRFAPDCUVGU-RUZDIDTESA-N 0.000 claims 1
- CYNGYKDELPIQQQ-OFSOJUDTSA-N (3R)-1-[3-[3-[3-[3-[[(1R)-2-hydroxy-1-phenylethyl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound OC[C@@H](C1=CC=CC=C1)NCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C CYNGYKDELPIQQQ-OFSOJUDTSA-N 0.000 claims 1
- CYNGYKDELPIQQQ-POURPWNDSA-N (3R)-1-[3-[3-[3-[3-[[(1S)-2-hydroxy-1-phenylethyl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound OC[C@H](C1=CC=CC=C1)NCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C CYNGYKDELPIQQQ-POURPWNDSA-N 0.000 claims 1
- CMCZELPZYAAQHT-OFSOJUDTSA-N (3R)-1-[3-[3-[3-[3-[[(2R)-2-hydroxy-2-phenylethyl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound O[C@@H](CNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)C1=CC=CC=C1 CMCZELPZYAAQHT-OFSOJUDTSA-N 0.000 claims 1
- IIPCFTKEDHLOME-FYBSXPHGSA-N (3R)-1-[3-[3-[3-[3-[[(2S)-2-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound ClC=1C=C(C=CC=1F)[C@@H](CNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)O IIPCFTKEDHLOME-FYBSXPHGSA-N 0.000 claims 1
- CMCZELPZYAAQHT-POURPWNDSA-N (3R)-1-[3-[3-[3-[3-[[(2S)-2-hydroxy-2-phenylethyl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound O[C@H](CNCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)C1=CC=CC=C1 CMCZELPZYAAQHT-POURPWNDSA-N 0.000 claims 1
- NUBHGLMREPGLGL-HHHXNRCGSA-N (3R)-1-[3-[3-[3-[3-[[1-(2-hydroxyethyl)piperidin-4-yl]amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound OCCN1CCC(CC1)NCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C NUBHGLMREPGLGL-HHHXNRCGSA-N 0.000 claims 1
- ADSFSZYYGNVUHL-GDLZYMKVSA-N (3R)-1-[3-[3-[3-[3-[benzyl(2-hydroxyethyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound C(C1=CC=CC=C1)N(CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)CCO ADSFSZYYGNVUHL-GDLZYMKVSA-N 0.000 claims 1
- BUGJYGHQJSWDBX-DNQXCXABSA-N (3R)-1-[3-[4-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-3-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC=C1OCCCN1C[C@@H](CC1)O)C1=C(C=C(C=C1)OCCCN1C[C@@H](CC1)O)C BUGJYGHQJSWDBX-DNQXCXABSA-N 0.000 claims 1
- FCCSWLNEJMUTJO-DNQXCXABSA-N (3R)-1-[3-[4-[4-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-3-methylphenoxy]propyl]pyrrolidin-3-ol Chemical compound CC1=C(C=CC(=C1)OCCCN1C[C@@H](CC1)O)C1=C(C=C(C=C1)OCCCN1C[C@@H](CC1)O)C FCCSWLNEJMUTJO-DNQXCXABSA-N 0.000 claims 1
- WUSFFJIDDPAQHQ-JWQCQUIFSA-N (3R)-1-[4-[3-[4-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]butyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCCCOC=1C(=C(C=CC=1)C1=C(C=C(C=C1)OCCCN1C[C@@H](CC1)O)C)C WUSFFJIDDPAQHQ-JWQCQUIFSA-N 0.000 claims 1
- WUVNULDMRXFGDS-CLJLJLNGSA-N (3R)-1-[5-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]pentyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCCCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C WUVNULDMRXFGDS-CLJLJLNGSA-N 0.000 claims 1
- KBELCPHWNGPHOG-CLJLJLNGSA-N (3R)-1-[5-[3-[4-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]pentyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCCCCOC=1C(=C(C=CC=1)C1=C(C=C(C=C1)OCCCN1C[C@@H](CC1)O)C)C KBELCPHWNGPHOG-CLJLJLNGSA-N 0.000 claims 1
- UBJPXBZEZGDPQH-NGDRWEMDSA-N (3S)-1-[3-[2-[3-[(3S)-3-hydroxypyrrolidin-1-yl]propoxy]-4-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]phenoxy]propyl]pyrrolidin-3-ol Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=CC(=C(C=C1)OCCCN1C[C@H](CC1)O)OCCCN1C[C@H](CC1)O)C UBJPXBZEZGDPQH-NGDRWEMDSA-N 0.000 claims 1
- GYYVGEMSSWKNMD-UIOOFZCWSA-N (3S)-1-[3-[3-[3-[3-[(3S)-3-carboxypiperidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]piperidine-3-carboxylic acid Chemical compound CC1=C(C=CC=C1OCCCN1C[C@H](CCC1)C(=O)O)C1=C(C(=CC=C1)OCCCN1C[C@H](CCC1)C(=O)O)C GYYVGEMSSWKNMD-UIOOFZCWSA-N 0.000 claims 1
- YSTRONQQJNRDRP-INNMJMHTSA-N (3S,4R)-4-(hydroxymethyl)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]piperidin-3-ol Chemical compound OC[C@@H]1[C@@H](CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)O YSTRONQQJNRDRP-INNMJMHTSA-N 0.000 claims 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 claims 1
- FBCPPJXBGRDJGH-DHIUTWEWSA-N 1-[2-[(3R)-3-hydroxypyrrolidin-1-yl]ethyl]-3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenyl]urea Chemical compound O[C@H]1CN(CC1)CCNC(=O)NC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C FBCPPJXBGRDJGH-DHIUTWEWSA-N 0.000 claims 1
- IYHHWMYWNOFUKT-UHFFFAOYSA-N 1-[3-[3-[3-[3-(4-carboxy-4-hydroxypiperidin-1-yl)propoxy]-2-chlorophenyl]-2-methylphenoxy]propyl]-4-hydroxypiperidine-4-carboxylic acid Chemical compound ClC1=C(C=CC=C1OCCCN1CCC(CC1)(C(=O)O)O)C1=C(C(=CC=C1)OCCCN1CCC(CC1)(C(=O)O)O)C IYHHWMYWNOFUKT-UHFFFAOYSA-N 0.000 claims 1
- GCVPODDPVKJAFV-UHFFFAOYSA-N 1-[3-[3-[3-[3-[(2,3-dihydroxy-3-methylbutyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]-3-methylbutane-2,3-diol Chemical compound CC1=C(C=CC=C1OCCCNCC(C(C)(O)C)O)C1=C(C(=CC=C1)OCCCNCC(C(C)(O)C)O)C GCVPODDPVKJAFV-UHFFFAOYSA-N 0.000 claims 1
- LULCOUVAHYGRRH-UHFFFAOYSA-N 1-[3-[3-[3-[3-[(2-hydroxy-3-methoxypropyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]-3-methoxypropan-2-ol Chemical compound CC1=C(C=CC=C1OCCCNCC(COC)O)C1=C(C(=CC=C1)OCCCNCC(COC)O)C LULCOUVAHYGRRH-UHFFFAOYSA-N 0.000 claims 1
- MEEQKUPPZLMINN-UHFFFAOYSA-N 1-[3-[3-[3-[3-[3-(dimethylamino)azetidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]-N,N-dimethylazetidin-3-amine Chemical compound CC1=C(C=CC=C1OCCCN1CC(C1)N(C)C)C1=C(C(=CC=C1)OCCCN1CC(C1)N(C)C)C MEEQKUPPZLMINN-UHFFFAOYSA-N 0.000 claims 1
- PKVXYGUTVSNABO-UHFFFAOYSA-N 1-[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[(1,3-thiazol-5-ylmethylamino)methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]-N-(1,3-thiazol-5-ylmethyl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CNCC1=CN=CS1)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CNCC1=CN=CS1)OC)C PKVXYGUTVSNABO-UHFFFAOYSA-N 0.000 claims 1
- OQLJKWTXDSBBGZ-UHFFFAOYSA-N 1-[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[(pyrimidin-5-ylmethylamino)methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]-N-(pyrimidin-5-ylmethyl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CNCC=1C=NC=NC=1)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CNCC=1C=NC=NC=1)OC)C OQLJKWTXDSBBGZ-UHFFFAOYSA-N 0.000 claims 1
- AHLVPOIIVXTDQO-UHFFFAOYSA-N 1-[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[[methyl(1,3-thiazol-5-ylmethyl)amino]methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]-N-methyl-N-(1,3-thiazol-5-ylmethyl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CN(C)CC1=CN=CS1)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CN(CC1=CN=CS1)C)OC)C AHLVPOIIVXTDQO-UHFFFAOYSA-N 0.000 claims 1
- VYBHXDNJGRZXKI-UHFFFAOYSA-N 1-[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[[methyl(pyrimidin-5-ylmethyl)amino]methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]-N-methyl-N-(pyrimidin-5-ylmethyl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CN(C)CC=1C=NC=NC=1)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CN(CC=1C=NC=NC=1)C)OC)C VYBHXDNJGRZXKI-UHFFFAOYSA-N 0.000 claims 1
- RRVFYOSEKOTFOG-UHFFFAOYSA-N 1-phenylpropane-1,3-diol Chemical compound OCCC(O)C1=CC=CC=C1 RRVFYOSEKOTFOG-UHFFFAOYSA-N 0.000 claims 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 claims 1
- BXGYYDRIMBPOMN-UHFFFAOYSA-N 2-(hydroxymethoxy)ethoxymethanol Chemical compound OCOCCOCO BXGYYDRIMBPOMN-UHFFFAOYSA-N 0.000 claims 1
- FEQRNSWYFUNMBT-UHFFFAOYSA-N 2-[4-[3-[3-[3-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]piperazin-1-yl]ethanol Chemical compound CC1=C(C=CC=C1OCCCN1CCN(CC1)CCO)C1=C(C(=CC=C1)OCCCN1CCN(CC1)CCO)C FEQRNSWYFUNMBT-UHFFFAOYSA-N 0.000 claims 1
- UBKKNWJGYLSDSJ-UHFFFAOYSA-N 2-methylpyridine-3-carbonitrile Chemical compound CC1=NC=CC=C1C#N UBKKNWJGYLSDSJ-UHFFFAOYSA-N 0.000 claims 1
- MZQHDBUGKAFSOC-UHFFFAOYSA-N 3-(hydroxymethyl)cyclopentane-1,2-diol Chemical compound OCC1CCC(O)C1O MZQHDBUGKAFSOC-UHFFFAOYSA-N 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims 1
- LRTIOPFTAVZGDF-UHFFFAOYSA-N 3-[3-[3-(3-aminopropoxy)-2-chlorophenyl]-2-chlorophenoxy]propan-1-amine Chemical compound ClC1=C(C=CC=C1OCCCN)C1=C(C(=CC=C1)OCCCN)Cl LRTIOPFTAVZGDF-UHFFFAOYSA-N 0.000 claims 1
- DPPKBYVYVIKDKP-DNQXCXABSA-N 3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-N-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propyl]-2-methylbenzamide Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)C(=O)NCCCN1C[C@@H](CC1)O)C)C DPPKBYVYVIKDKP-DNQXCXABSA-N 0.000 claims 1
- GENGVMRZRFNOHU-UHFFFAOYSA-N 3-[3-[3-[3-[3-(2,3-dihydroxypropylamino)propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]propane-1,2-diol Chemical compound CC1=C(C=CC=C1OCCCNCC(CO)O)C1=C(C(=CC=C1)OCCCNCC(CO)O)C GENGVMRZRFNOHU-UHFFFAOYSA-N 0.000 claims 1
- MOJOPLVNLDALBN-UHFFFAOYSA-N 3-[3-[3-[3-[3-[(2,3-dihydroxy-2-methylpropyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propylamino]-2-methylpropane-1,2-diol Chemical compound CC1=C(C=CC=C1OCCCNCC(CO)(O)C)C1=C(C(=CC=C1)OCCCNCC(CO)(O)C)C MOJOPLVNLDALBN-UHFFFAOYSA-N 0.000 claims 1
- BAHOFAAZPNHRPT-UHFFFAOYSA-N 3-[3-[3-[3-[3-[2,3-dihydroxypropyl(methyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl-methylamino]propane-1,2-diol Chemical compound CC1=C(C=CC=C1OCCCN(C)CC(CO)O)C1=C(C(=CC=C1)OCCCN(C)CC(CO)O)C BAHOFAAZPNHRPT-UHFFFAOYSA-N 0.000 claims 1
- WWZTVSPTWIARAF-UHFFFAOYSA-N 3-[3-[3-[3-[3-[3-hydroxypropyl(methyl)amino]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl-methylamino]propan-1-ol Chemical compound CC1=C(C=CC=C1OCCCN(C)CCCO)C1=C(C(=CC=C1)OCCCN(C)CCCO)C WWZTVSPTWIARAF-UHFFFAOYSA-N 0.000 claims 1
- QIZKGCRMTFTWJX-RUZDIDTESA-N 3-[[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]methyl]benzonitrile Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCC=1C=C(C#N)C=CC=1)C)C QIZKGCRMTFTWJX-RUZDIDTESA-N 0.000 claims 1
- JQCMHJACDLHSJL-LJQANCHMSA-N 3-[[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenyl]carbamoylamino]propanoic acid Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)NC(NCCC(=O)O)=O)C)C JQCMHJACDLHSJL-LJQANCHMSA-N 0.000 claims 1
- QWHDXIUUXWGQME-UHFFFAOYSA-N 3-hydroxy-4-oxobutanoic acid Chemical compound O=CC(O)CC(O)=O QWHDXIUUXWGQME-UHFFFAOYSA-N 0.000 claims 1
- CSIFGMFVGDBOQC-UHFFFAOYSA-N 3-iminobutanenitrile Chemical compound CC(=N)CC#N CSIFGMFVGDBOQC-UHFFFAOYSA-N 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- GMEAPCFBZDJCRS-CLJLJLNGSA-N N-[(3R)-1-[3-[3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylphenoxy]propyl]pyrrolidin-3-yl]acetamide Chemical compound O[C@H]1CN(CC1)CCCOC=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)NC(C)=O)C)C GMEAPCFBZDJCRS-CLJLJLNGSA-N 0.000 claims 1
- VVPFKRICWPTQLB-DHIUTWEWSA-N N-[2-[(3R)-3-hydroxypyrrolidin-1-yl]ethyl]-3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylbenzamide Chemical compound O[C@H]1CN(CC1)CCNC(=O)C=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C VVPFKRICWPTQLB-DHIUTWEWSA-N 0.000 claims 1
- TYUMPIQEKPMLHD-DHIUTWEWSA-N N-[2-[(3R)-3-hydroxypyrrolidin-1-yl]ethyl]-3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylbenzenesulfonamide Chemical compound O[C@H]1CN(CC1)CCNS(=O)(=O)C=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C TYUMPIQEKPMLHD-DHIUTWEWSA-N 0.000 claims 1
- MPKFZOCLDPDKFM-JOCHJYFZSA-N N-[3-(dimethylamino)propyl]-3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylbenzenesulfonamide Chemical compound CN(CCCNS(=O)(=O)C=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C)C MPKFZOCLDPDKFM-JOCHJYFZSA-N 0.000 claims 1
- MKBOKGOFMOYXHG-JWQCQUIFSA-N N-[4-[(3R)-3-hydroxypyrrolidin-1-yl]butyl]-3-[3-[3-[(3R)-3-hydroxypyrrolidin-1-yl]propoxy]-2-methylphenyl]-2-methylbenzamide Chemical compound O[C@H]1CN(CC1)CCCCNC(=O)C=1C(=C(C=CC=1)C1=C(C(=CC=C1)OCCCN1C[C@@H](CC1)O)C)C MKBOKGOFMOYXHG-JWQCQUIFSA-N 0.000 claims 1
- MKFNPSFGUSMRQI-UHFFFAOYSA-N N-[[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[(1H-pyrazol-5-ylmethylamino)methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]methyl]-1-(1H-pyrazol-5-yl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CNCC1=NNC=C1)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CNCC1=NNC=C1)OC)C MKFNPSFGUSMRQI-UHFFFAOYSA-N 0.000 claims 1
- OOYLQBLGASEEEY-UHFFFAOYSA-N N-[[5-chloro-4-[[3-[3-[[2-chloro-5-methoxy-4-[[methyl(1H-pyrazol-5-ylmethyl)amino]methyl]phenoxy]methyl]-2-methylphenyl]-2-methylphenyl]methoxy]-2-methoxyphenyl]methyl]-N-methyl-1-(1H-pyrazol-5-yl)methanamine Chemical compound CC1=C(C=CC=C1COC1=CC(=C(C=C1Cl)CN(CC1=NNC=C1)C)OC)C1=C(C(=CC=C1)COC1=CC(=C(C=C1Cl)CN(C)CC1=NNC=C1)OC)C OOYLQBLGASEEEY-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 125000006371 dihalo methyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004970 halomethyl group Chemical group 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- QAABAIHPYHVVMQ-UHFFFAOYSA-N n-(2-pyridin-4-ylethyl)propan-1-amine Chemical compound CCCNCCC1=CC=NC=C1 QAABAIHPYHVVMQ-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- IZXWMVPZODQBRB-UHFFFAOYSA-N piperidine-3,4-diol Chemical compound OC1CCNCC1O IZXWMVPZODQBRB-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 125000004953 trihalomethyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382480P | 2016-09-01 | 2016-09-01 | |
| US62/382,480 | 2016-09-01 | ||
| US15/689,115 | 2017-08-29 | ||
| US15/689,115 US10144706B2 (en) | 2016-09-01 | 2017-08-29 | Compounds useful as immunomodulators |
| PCT/US2017/049252 WO2018044963A1 (en) | 2016-09-01 | 2017-08-30 | Biaryl compounds useful as immunomodulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531274A JP2019531274A (ja) | 2019-10-31 |
| JP2019531274A5 true JP2019531274A5 (OSRAM) | 2020-10-08 |
| JP7155110B2 JP7155110B2 (ja) | 2022-10-18 |
Family
ID=61241693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511947A Active JP7155110B2 (ja) | 2016-09-01 | 2017-08-30 | 免疫調節剤として有用なビアリール化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10144706B2 (OSRAM) |
| EP (1) | EP3507284B1 (OSRAM) |
| JP (1) | JP7155110B2 (OSRAM) |
| KR (1) | KR102497068B1 (OSRAM) |
| CN (1) | CN109863146B (OSRAM) |
| AR (1) | AR109471A1 (OSRAM) |
| AU (1) | AU2017319323A1 (OSRAM) |
| BR (1) | BR112019004100A2 (OSRAM) |
| CA (1) | CA3035697A1 (OSRAM) |
| EA (1) | EA201990495A1 (OSRAM) |
| ES (1) | ES2919298T3 (OSRAM) |
| MA (1) | MA46091A (OSRAM) |
| MX (1) | MX2019002356A (OSRAM) |
| SG (1) | SG11201901700UA (OSRAM) |
| TW (1) | TW201815764A (OSRAM) |
| WO (1) | WO2018044963A1 (OSRAM) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| KR102401963B1 (ko) | 2016-06-27 | 2022-05-25 | 케모센트릭스, 인크. | 면역조절제 화합물 |
| IL308894A (en) | 2016-10-14 | 2024-01-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| EP3558970B1 (en) | 2016-12-20 | 2021-09-01 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| CN108250159B (zh) * | 2016-12-29 | 2023-07-11 | 深圳微芯生物科技股份有限公司 | 脲类化合物、其制备方法及其应用 |
| CN110461829B (zh) | 2017-03-27 | 2023-02-28 | 百时美施贵宝公司 | 作为免疫调节剂的取代的异喹啉衍生物 |
| JOP20180040A1 (ar) * | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
| WO2019008156A1 (en) * | 2017-07-07 | 2019-01-10 | Rijksuniversiteit Groningen | INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1 |
| US10919852B2 (en) | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
| KR102670486B1 (ko) | 2017-08-08 | 2024-05-28 | 케모센트릭스, 인크. | 마크로사이클릭 면역조절제 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| JP7386796B2 (ja) | 2017-11-14 | 2023-11-27 | グリーン クロス ラボ セル コーポレーション | 抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体 |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| KR102738303B1 (ko) | 2018-01-23 | 2024-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 2,8-디아실-2,8-디아자스피로[5.5]운데칸 화합물 |
| MY196582A (en) | 2018-02-13 | 2023-04-19 | Gilead Sciences Inc | PD-1/PD-L1 Inhibitors |
| EP3755311A4 (en) | 2018-02-22 | 2021-11-10 | ChemoCentryx, Inc. | INDANAMINE AS PD-L1 ANTAGONISTS |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| WO2019169123A1 (en) | 2018-03-01 | 2019-09-06 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CA3093851A1 (en) | 2018-03-29 | 2019-10-03 | Arbutus Biopharma Corporation | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| US12331068B2 (en) | 2018-05-31 | 2025-06-17 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting CD73 |
| PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
| CN112424185B (zh) * | 2018-07-13 | 2024-05-17 | 广州丹康医药生物有限公司 | 含苯环的化合物、其制备方法及应用 |
| TWI869058B (zh) | 2018-07-27 | 2025-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN109305934A (zh) * | 2018-08-07 | 2019-02-05 | 成都海博锐药业有限公司 | 苯醚类衍生物及可药用盐、医药上的用途 |
| CN110872275A (zh) * | 2018-08-31 | 2020-03-10 | 深圳微芯生物科技股份有限公司 | 作为免疫调节剂的联苯化合物及其用途 |
| EP3870566A1 (en) | 2018-10-24 | 2021-09-01 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| PL3873903T3 (pl) | 2018-10-31 | 2024-05-20 | Gilead Sciences, Inc. | Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1 |
| SG11202105850YA (en) | 2018-11-02 | 2021-07-29 | Shanghai Maxinovel Pharmaceuticals Co Ltd | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof |
| TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| EP3908600A1 (en) * | 2019-01-11 | 2021-11-17 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Fusion protein with immunosuppressive activity |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3946628A1 (en) | 2019-03-28 | 2022-02-09 | Bristol-Myers Squibb Company | Methods of treating tumor |
| KR20210146348A (ko) | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| MA55974A (fr) | 2019-05-15 | 2022-03-23 | Chemocentryx Inc | Composés triaryles pour le traitement de maladies pd-l1 |
| WO2020237081A1 (en) * | 2019-05-21 | 2020-11-26 | Bristol-Myers Squibb Company | Immunomodulators |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| CN112028870B (zh) * | 2019-06-04 | 2021-11-05 | 中国科学院上海药物研究所 | 一种具有苄氧基芳环结构的化合物，其制备方法和用途 |
| SG11202112875UA (en) | 2019-06-20 | 2021-12-30 | Chemocentryx Inc | Compounds for treatment of pd-l1 diseases |
| CN114206338B (zh) | 2019-07-10 | 2025-12-12 | 凯莫森特里克斯股份有限公司 | 作为pd-l1抑制剂的二氢化茚类 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN111909108B (zh) * | 2019-09-02 | 2023-05-02 | 中国药科大学 | 联苯类化合物及其制备方法和医药用途 |
| AU2020350795A1 (en) | 2019-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Quantitative spatial profiling for LAG-3 antagonist therapy |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| KR20220079893A (ko) * | 2019-10-04 | 2022-06-14 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 화합물 |
| CR20220216A (es) | 2019-10-16 | 2023-01-09 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
| PE20221445A1 (es) | 2019-10-16 | 2022-09-21 | Chemocentryx Inc | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 |
| EP4054723A1 (en) | 2019-11-08 | 2022-09-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
| EP4567109A3 (en) | 2019-12-06 | 2025-09-17 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| TW202421168A (zh) | 2020-03-20 | 2024-06-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
| IL297908A (en) | 2020-05-05 | 2023-01-01 | Teon Therapeutics Inc | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
| EP4204095A1 (en) | 2020-08-28 | 2023-07-05 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022052926A1 (zh) | 2020-09-09 | 2022-03-17 | 广州再极医药科技有限公司 | 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用 |
| JP2023541389A (ja) | 2020-09-11 | 2023-10-02 | ナミ セラピューティクス， インコーポレイテッド | がんの処置において有用なｐｄ－１アンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 |
| WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| US20240181052A1 (en) | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| CN113135895A (zh) * | 2021-04-30 | 2021-07-20 | 中国药科大学 | 一种新型联苯类衍生物及其制备方法与医药用途 |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| EP4351564A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| CN115677665B (zh) * | 2021-07-26 | 2024-04-19 | 中国药科大学 | 含联苯类衍生物及其医药用途 |
| WO2023034530A1 (en) | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
| WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
| WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
| CN118765285A (zh) | 2022-01-26 | 2024-10-11 | 百时美施贵宝公司 | 用于肝细胞癌的组合疗法 |
| US20230326022A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures |
| WO2024015372A1 (en) | 2022-07-14 | 2024-01-18 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
| CN120731228A (zh) | 2022-12-21 | 2025-09-30 | 百时美施贵宝公司 | 肺癌的组合疗法 |
| KR20250150141A (ko) | 2023-02-23 | 2025-10-17 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 피리도피리미딘 유도체 및 이의 용도 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU75628A1 (OSRAM) | 1976-08-19 | 1978-04-13 | ||
| CH654286A5 (de) * | 1981-11-04 | 1986-02-14 | Ciba Geigy Ag | Verfahren zur pd-katalysierten arylierung von olefinen mit arylhalogeniden. |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5977117A (en) | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| AU2003281040A1 (en) | 2002-07-10 | 2004-02-02 | Sumitomo Pharmaceuticals Co., Ltd. | Biaryl derivatives |
| JP2006523196A (ja) | 2003-03-11 | 2006-10-12 | ニューロサーチ、アクティーゼルスカブ | 新規ｋｃｎｑチャネルを調節する化合物及びその医薬用途 |
| JP2005179281A (ja) | 2003-12-19 | 2005-07-07 | Sumitomo Pharmaceut Co Ltd | ビフェニル化合物 |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| AU2006277786B2 (en) | 2005-08-09 | 2012-09-06 | Asterand Uk Acquisition Limited | EP2 receptor agonists |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| CA2683751C (en) | 2007-04-16 | 2013-01-08 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
| TW200932219A (en) * | 2007-10-24 | 2009-08-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| TWI444467B (zh) | 2010-05-27 | 2014-07-11 | Angus Chemical | 用於液體碳氫化合物及其他燃料與油之標記物化合物 |
| WO2015034820A1 (en) * | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CA2990279C (en) * | 2015-06-29 | 2022-07-05 | Vanderbilt University | Intravenous administration of citrulline during surgery |
| US10745382B2 (en) * | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| BR112019000247A2 (pt) | 2016-07-08 | 2019-04-16 | Bristol-Myers Squibb Company | derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores |
| JP2019530732A (ja) * | 2016-08-03 | 2019-10-24 | アライジング・インターナショナル・インコーポレイテッドＡｒｉｓｉｎｇ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｉｎｃ． | 免疫モジュレータとして有用な対称または半対称化合物 |
-
2017
- 2017-08-29 US US15/689,115 patent/US10144706B2/en active Active
- 2017-08-30 KR KR1020197008795A patent/KR102497068B1/ko active Active
- 2017-08-30 ES ES17764981T patent/ES2919298T3/es active Active
- 2017-08-30 MX MX2019002356A patent/MX2019002356A/es unknown
- 2017-08-30 AR ARP170102407A patent/AR109471A1/es unknown
- 2017-08-30 CN CN201780067319.8A patent/CN109863146B/zh active Active
- 2017-08-30 AU AU2017319323A patent/AU2017319323A1/en not_active Abandoned
- 2017-08-30 CA CA3035697A patent/CA3035697A1/en not_active Abandoned
- 2017-08-30 SG SG11201901700UA patent/SG11201901700UA/en unknown
- 2017-08-30 EP EP17764981.1A patent/EP3507284B1/en active Active
- 2017-08-30 JP JP2019511947A patent/JP7155110B2/ja active Active
- 2017-08-30 BR BR112019004100A patent/BR112019004100A2/pt not_active Application Discontinuation
- 2017-08-30 WO PCT/US2017/049252 patent/WO2018044963A1/en not_active Ceased
- 2017-08-30 EA EA201990495A patent/EA201990495A1/ru unknown
- 2017-08-30 TW TW106129492A patent/TW201815764A/zh unknown
- 2017-08-30 MA MA046091A patent/MA46091A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531274A5 (OSRAM) | ||
| JP7609854B2 (ja) | Ｍａｇｌ阻害剤としての４，４ａ，５，７，８，８ａ－ヘキサピリド［４，３－ｂ］［１，４］オキサジン－３－オン化合物 | |
| US8778951B2 (en) | Heteroaryl compounds and their uses | |
| ES2942319T3 (es) | Inhibidores de oxacina monoacilglicerol lipasa (MAGL) | |
| US9085540B2 (en) | Pyrazinecarboxamide compound | |
| US10751332B2 (en) | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | |
| TWI583670B (zh) | Partially saturated nitrogenous heterocyclic compounds | |
| US9662330B2 (en) | Aminopyrimidine derivatives for use as modulators of kinase activity | |
| US20120157433A1 (en) | Heteroaryl Compounds as Kinase Inhibitors | |
| RU2016137674A (ru) | Производные пиперидиндиона | |
| US20130303507A1 (en) | Substituted hetero-biaryl compounds and their uses | |
| EA032609B1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
| HK1046866A1 (zh) | 3(5)-氨基-吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途 | |
| US20110130380A1 (en) | Heteroaryl Kinase Inhibitors | |
| WO2012101065A2 (en) | Pyrimidine biaryl amine compounds and their uses | |
| WO2012101066A1 (en) | Pyridine biaryl amine compounds and their uses | |
| JP6454418B2 (ja) | ピラゾール誘導体、またはその薬理学的に許容される塩 | |
| KR20120076352A (ko) | 증식성 질환의 치료에 유용한 피라지닐피리딘 | |
| JP7114591B2 (ja) | Ｇｓｋ－３阻害剤 | |
| WO2015012400A1 (ja) | グリシントランスポーター阻害物質 | |
| WO2015163472A1 (ja) | トリアゾリルで置換されたヘテロアリール化合物 | |
| JP6569678B2 (ja) | ２−アミノチアゾール誘導体またはその塩 | |
| HK40062310A (en) | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |